Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex
- 28 November 2006
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 103 (48) , 18243-18248
- https://doi.org/10.1073/pnas.0608545103
Abstract
The development of protein subunit vaccines to combat some of the world9s deadliest pathogens such as a malaria parasite, Plasmodium falciparum, is stalled, due in part to the inability to induce and sustain high-titer antibody responses. Here, we show the induction of persistent, high-titer antibody responses to recombinant Pfs25H, a human malarial transmission-blocking protein vaccine candidate, after chemical conjugation to the outer-membrane protein complex (OMPC) of Neisseria meningitidis serogroup B and adsorption to aluminum hydroxyphosphate. In mice, the Pfs25H-OMPC conjugate vaccine was >1,000 times more potent in generating anti-Pfs25H ELISA reactivity than a similar 0.5-μg dose of Pfs25H alone in Montanide ISA720, a water-in-oil adjuvant. The immune enhancement requires covalent conjugation between Pfs25H and the OMPC, given that physically mixed Pfs25H and OMPC on aluminum hydroxyphosphate failed to induce greater activity than the nonconjugated Pfs25H on aluminum hydroxyphosphate. The conjugate vaccine Pfs25H-OMPC also was highly immunogenic in rabbits and rhesus monkeys. In rhesus monkeys, the antibody responses were sustained over 18 months, at which time another vaccination with nonconjugated Pfs25H induced strong anamnestic responses. The vaccine-induced anti-Pfs25-specific antibodies in all animal species blocked the transmission of parasites to mosquitoes. Protein antigen conjugation to OMPC or other protein carrier may have general application to a spectrum of protein subunit vaccines to increase immunogenicity without the need for potentially reactogenic adjuvants.Keywords
This publication has 26 references indexed in Scilit:
- Revisiting Freund's incomplete adjuvant for vaccines in the developing worldTrends in Parasitology, 2005
- Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malariaVaccine, 2005
- Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeysVaccine, 2004
- Analysis of Immunological Nonresponsiveness to the 19-Kilodalton Fragment of Merozoite Surface Protein 1 ofPlasmodium yoelii: Rescue by Chemical Conjugation to Diphtheria Toxoid (DT) and Enhancement of Immunogenicity by Prior DT VaccinationInfection and Immunity, 2003
- Carrier-mediated enhancement of cognate T cell help: the basis for enhanced immunogenicity of meningococcal outer membrane protein polysaccharide conjugate vaccineEuropean Journal of Immunology, 2001
- Recent Advances in the Large Scale Fermentation of Neisseria meningitidis Group B for the Production of an Outer Membrane Protein ComplexNature Biotechnology, 1995
- Acidic derivatives of homocysteine thiolactone: utility as anionic linkersBioconjugate Chemistry, 1992
- Comparative immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugate vaccinesVaccine, 1991
- Bimolecular chemistry of macromolecules: synthesis of bacterial polysaccharide conjugates with Neisseria meningitidis membrane proteinJournal of the American Chemical Society, 1986
- Crystal and molecular structure of the charge-transfer salt of decamethylferrocenium and tricyanomethanide, [Fe(C5Me5)2]+/[C(CN)3]-. The electronic structure and spectra of the tricyanomethanide ionJournal of the American Chemical Society, 1986